KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacific Biosciences Of California (PACB) Equity Average (2016 - 2026)

Pacific Biosciences Of California has reported Equity Average over the past 15 years, most recently at $20.7 million for Q4 2025.

  • For Q4 2025, Equity Average fell 95.68% year-over-year to $20.7 million; the TTM value through Dec 2025 reached $20.7 million, down 95.68%, while the annual FY2025 figure was $256.0 million, 57.62% down from the prior year.
  • Equity Average for Q4 2025 was $20.7 million at Pacific Biosciences Of California, down from $48.8 million in the prior quarter.
  • Over five years, Equity Average peaked at $762.8 million in Q1 2022 and troughed at $20.7 million in Q4 2025.
  • A 5-year average of $481.7 million and a median of $582.8 million in 2022 define the central range for Equity Average.
  • Biggest five-year swings in Equity Average: surged 434.2% in 2021 and later tumbled 95.68% in 2025.
  • Year by year, Equity Average stood at $269.4 million in 2021, then soared by 120.77% to $594.7 million in 2022, then grew by 23.17% to $732.5 million in 2023, then plummeted by 34.49% to $479.9 million in 2024, then tumbled by 95.68% to $20.7 million in 2025.
  • Business Quant data shows Equity Average for PACB at $20.7 million in Q4 2025, $48.8 million in Q3 2025, and $76.6 million in Q2 2025.